Precision medicine – medicine’s solution to diversity?
-
Elisabeth-Herz-Kremenak-Saal
Plenary
/
in englischer SpracheA paradigm shift in the field of medicine: precision medicine! Diversity, the basis of this revolutionary development, is significantly changing medicine towards personalized methods of treatment. What advantages does this have for individual patients? Are we seeing a medical revolution? And what does that mean for the technologies of tomorrow?
| |||||
| |||||
| |||||
| |||||
|
Dr. MD Christian J. HEROLD
Leiter, Abteilung für Allgemeine Radiologie und Kinderradiologie, Medizinische Universität Wien
| 1973-1979 | Medical Training - University of Vienna |
| 1979 | Graduation M.D. |
| 1979-1984 | Internship and Training as General Practitioner |
| 1984 | Board Certification as GP |
| 1984-1989 | Residency in Radiology - University of Vienna |
| 09.1989 Board Certification | |
| 1989-1991 | Postdoctoral Training |
| Research Fellowship in Chest Radiology and MR Imaging, Dept. of Radiology Johns Hopkins University, Baltimore, USA | |
| since 1992 | Faculty member (part time), Dept. of Radiology, Johns Hopkins Hospital, Baltimore USA |
| Chief Executive Officer of MUVI (Medical University of Vienna International Hospital Operations) | |
| Designated Chairman; Department of Radiology and Radiologic Clinics, Medical University of Vienna (from 10/2008) | |
| Director, International Affairs, Medical University of Vienna | |
| Vienna Health Council, Board Member |
Ph.D. Peter NILSSON
Professor in Proteomics and Scientific Director, SciLifeLab, Department of Protein Science, KTH - Royal Institute of Technology, Stockholm
| 1993 | M.Sc., Biotechnology, KTH Royal Institute of Technology, Stockholm |
| 1999 | Ph.D., Biotechnology, KTH Royal Institute of Technology, Stockholm |
| since 2002 | Head, Affinity Proteomics research group, KTH Royal Institute of Technology, Stockholm |
| 2007 | Associate professor, Biotechnology, KTH Royal Institute of Technology, Stockholm |
| 2011 | Professor in Proteomics, KTH Royal Institute of Technology, Stockholm |
| 2011-2016 | Site Director, Human Protein Atlas, SciLifeLab Stockholm |
| 2014-2017 | Director, SciLifeLab Affinity Proteomics national platform, Solna |
| Vice Dean, School of Biotechnology, KTH Royal Institute of Technology, Stockholm | |
| since 2014 | Director, SciLifeLab Autoimmunity profiling facility, Solna |
| since 2017 | Scientific Director, SciLifeLab, KTH Royal Institute of Technology, Stockholm |
Ph.D. Patrice MILOS
President and CEO, Medley Genomics, Providence, RI
| 1980-1984 | Ph.D., Biology, Rensselaer Polytechnic Institute, NY |
| 1984-1987 | Post-Doctoral Fellow, The Biological Laboratories, Harvard University, MA |
| 1987-1990 | Post-Doctoral Fellow, Brown University, RI |
| 1993-2007 | Executive Director, Global Research & Development, Pfizer Inc., CT |
| Executive Director, Translational and Molecular Medicine, Pfizer Inc., CT. | |
| 2007-2011 | Senior Vice President; CSO, Helicos BioSciences, MA |
| 2011-2013 | Site Head, Centers for Therapeutic Innovation, Pfizer Inc., MA |
| 2013-2016 | President, CEO, Claritas Genomics, MA |
| since 2015 | Scientific Advisor SeqLL - ULTRAPLACAD - Baby's First Test |
| since 2016 | Co-Founder, President and CEO, Medley Genomics, RI |
| since 2017 | Board of Directors, MedMates, RI BIO Affiliate, RI |
| since 2018 | Scientific Advisor, Atlas Genetics, Trowbridge |
DI Dr. Michaela FRITZ
Vice Rector for Research and Innovation, Medical University of Vienna; Member of the Steering Committee, European Forum Alpbach, Vienna
| 1989-1994 | Master studies, Department of Materials Science, ETH Zurich |
| 1994-1995 | Diploma thesis, Washington Research Centre, W. R. Grace, Columbia, Maryland, MD |
| 1995-1998 | Research assistant; Teaching assistant, Laboratory for Surface Science and Technology, ETH Zurich |
| 1996-2000 | Ph.D. studies, Department of Materials Science, ETH Zurich |
| 2000-2001 | Ph.D. scientist, Department of Chemical Engineering, University of California, Berkeley, CA |
| 2001-2004 | Business development, Bioscience, Infineon Technologies AG, Munich |
| 2005-2010 | Head, LISA - Life Sciences Austria, Technology & Innovation, Austria Wirtschaftsservice GmbH, Vienna |
| 2006-2010 | Managing Director, LISA VR, Life Science Austria Vienna Region, Vienna |
| 2010-2015 | Head, Department Health and Environment, AIT - Austrian Institute of Technology, Vienna |
| 2012-2016 | President, AAL Austria, Vienna |
| since 2015 | Vice-Rector, Research and Innovation, Medical University Vienna |
| Member, Scientific Advisory Committee, Joanneum Research, Vienna | |
| since 2018 | Head, Scientific Advisory Committee Health Symposium and Member of the Steering Committee, European Forum Alpbach, Vienna |
Dr. Giulio SUPERTI-FURGA
Professor, Institute of Pharmacology, Medical University of Vienna; Scientific Director, CeMM - Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna
| 1987-1991 | Ph.D., Molecular Biology, University of Zurich |
| 1991-1993 | Postdoctoral fellow, EMBO and EU Postdoc EMBL - European Molecular Biology Laboratory, Heidelberg |
| 1993-2004 | Staff Scientist, Team Leader; EMBL - European Molecular Biology Laboratory, Heidelberg |
| 1997-2000 | Guest Professor, Molecular Biology, University of Bologna |
| 2000-2005 | Founder and Scientific Director, Cellzome AG and Inc., Heidelberg and Cambridge |
| 2005-2014 | Guest Professor, Molecular Pharmacology, Medical University of Vienna |
| since 2005 | Director, CeMM - Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna |
| since 2015 | Professor, Medical Systems Biology, Center for Physiology and Pharmacology, Medical University of Vienna |
| since 2017 | Member, Scientific Council of the European Research Council, Brussels |
